A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors

NCT01760525 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor With p53 Wild Type Status

Interventions

DRUG: CGM097

Sponsor

Novartis Pharmaceuticals